Sanofi $SNY Holdings Raised by Transcend Capital Advisors LLC

Transcend Capital Advisors LLC boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 21.6% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 4,738 shares of the company’s stock after buying an additional 843 shares during the period. Transcend Capital Advisors LLC’s holdings in Sanofi were worth $229,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Capital Analysts LLC raised its position in Sanofi by 14.0% during the first quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock valued at $92,000 after buying an additional 204 shares during the period. Thomasville National Bank raised its position in Sanofi by 0.3% during the second quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock valued at $3,886,000 after buying an additional 211 shares during the period. Hexagon Capital Partners LLC raised its position in Sanofi by 4.2% during the first quarter. Hexagon Capital Partners LLC now owns 5,959 shares of the company’s stock valued at $330,000 after buying an additional 238 shares during the period. U.S. Capital Wealth Advisors LLC raised its position in Sanofi by 4.1% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 6,227 shares of the company’s stock valued at $301,000 after buying an additional 247 shares during the period. Finally, Whipplewood Advisors LLC raised its position in Sanofi by 18.2% during the second quarter. Whipplewood Advisors LLC now owns 1,606 shares of the company’s stock valued at $78,000 after buying an additional 247 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of SNY stock opened at $50.94 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.94. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The stock’s 50-day moving average is $48.71 and its two-hundred day moving average is $49.56. The firm has a market cap of $125.08 billion, a P/E ratio of 11.93, a PEG ratio of 1.38 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 24th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.10. The business had revenue of $14.53 billion for the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The firm’s revenue for the quarter was down 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.25 EPS. Analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on SNY shares. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, October 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research report on Monday. Finally, Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.